Loncastuximab tesirine monotherapy (R/R DLBCL, 3L+; LOTIS-2)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-LONCASTUXIMAB-TESIRINE |
|---|
| ID | REG-LONCASTUXIMAB-TESIRINE |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-30 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-DLBCL-2024 SRC-LOTIS-2-CAIMI-2021 SRC-NCCN-BCELL-2025 |
Notes
LOTIS-2 (Caimi Lancet Oncol 2021): single-arm phase 2, 145 r/r DLBCL patients ≥2 prior lines, ORR 48%, CR 24%, mDoR 13.4 mo in responders, mPFS 4.9 mo, mOS 9.5 mo. Indicated 3L+ for r/r DLBCL NOS, HGBL, DLBCL arising from low-grade lymphoma. Off-the-shelf, outpatient, no CRS / ICANS — operational advantages over CAR-T and bispecifics. Pairs with IND-DLBCL-3L-LONCASTUXIMAB; intended for non-CAR-T-eligible frail patients. Edema management + photoprotection are dominant monitoring foci; cytopenia recovery often >day 21, expect cycle delays.
Used By
Indication
IND-DLBCL-3L-LONCASTUXIMAB- IND-DLBCL-3L-LONCASTUXIMAB